Exosomal miR-543 Inhibits the Proliferation of Ovarian Cancer by Targeting IGF2
Shupei Zhang(Fujian Medical University), Yi Huan(Fujian Medical University)
Cited by 12
Related Papers
A randomized Phase III trial of neoadjuvant recombinant human endostatin, docetaxel and epirubicin as first‐line therapy for patients with breast cancer (<scp>CBCRT</scp>01)
|International Journal of Cancer|2017|30
Downregulation of RIPK4 Expression Inhibits Epithelial-Mesenchymal Transition in Ovarian Cancer through IL-6
|Journal of Immunology Research|2021|13